Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model

• DOI: 10.1126/sciadv.ado4288
• Publication Date: 2024-08-30T17:59:03Z
• Authors: Michelle R. Garnsey; Matthew C. Robinson; Luong T. Nguyen; Rhonda Cardin; Joseph Tillotson; Ellene Mashalidis; Aijia Yu; Lisa Aschenbrenner; Amanda Balesano; Amin Behzadi; Britton Boras; Jeanne S. Chang; Heather Eng; Andrew Ephron; Tim Foley; Kristen K. Ford; James M. Frick; Scott Gibson; Li Hao; Brett Hurst; Amit S. Kalgutkar; Magdalena Korczynska; Zsofia Lengyel-Zhand; Liping Gao; Hannah R. Meredith; Nandini C. Patel; Jana Polivkova; Devendra Rai; Colin R. Rose; Hussin Rothan; Sylvie K. Sakata; Thomas R. Vargo; Wenying Qi; Huixian Wu; Yiping Liu; Irina Yurgelonis; Jinzhi Zhang; Yuao Zhu; Lei Zhang; Alpha A. Lee
• Keywords: 2019-20 coronavirus outbreak; Protease inhibitor (pharmacology); Coronavirus Infections

Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy potential viral resistance. The SARS-CoV-2 papain-like protease (PL